Lunesta vs Trazodone: Head-to-Head Efficacy for Insomnia

Why These Two Drugs Get Compared

Eszopiclone and trazodone sit at opposite ends of the insomnia prescribing spectrum. Eszopiclone earned its FDA indication through rigorous phase III programs, while trazodone became the most-prescribed sleep medication in the United States without ever receiving a sleep-specific approval from the FDA [1].

Clinicians often face a choice between a drug that has the data but carries a controlled-substance classification, and one that sidesteps scheduling concerns but leans on thinner evidence. A 2014 analysis published in the BMJ estimated that trazodone accounted for roughly 45% of all prescriptions written specifically for insomnia in ambulatory U.S. visits, outpacing every FDA-approved hypnotic 2. That gap between prescribing volume and evidence depth is what makes this comparison clinically relevant.

The absence of a published head-to-head randomized trial means any comparison must synthesize data across separate study populations. This article does exactly that, pulling from the best available evidence for each agent and flagging where indirect comparison limits the conclusions.

Mechanism of Action: Different Pathways to Sleep

Eszopiclone binds to the benzodiazepine site on GABA-A receptors, enhancing inhibitory neurotransmission. It is the S-enantiomer of racemic zopiclone and belongs to the cyclopyrrolone class of non-benzodiazepine hypnotics 3.

Trazodone's sedating effect comes mainly from antagonism at 5-HT2A serotonin receptors and histamine H1 receptors at the low doses used for sleep (25 to 100 mg). At full antidepressant doses (150 to 400 mg), the drug also inhibits serotonin reuptake, but this mechanism plays a negligible role at the typical sleep dose 4.

The distinction matters pharmacologically. Eszopiclone acts on the same receptor system as benzodiazepines and shares a similar side-effect profile (tolerance risk, rebound insomnia, complex sleep behaviors). Trazodone avoids GABAergic effects but introduces serotonergic and adrenergic side effects, including orthostatic hypotension, dry mouth, and, rarely, priapism in male patients 4.

Eszopiclone Efficacy Data

The strongest evidence for eszopiclone comes from a six-month double-blind, placebo-controlled trial by Krystal et al. published in Sleep in 2003. That study enrolled 788 adults with primary insomnia and randomized them to eszopiclone 3 mg or placebo nightly for 44 weeks, including an initial six-month double-blind phase and a two-week single-blind placebo run-out 1.

Key results from Krystal 2003 (N=788):

• Sleep-onset latency (SOL): Subjective SOL improved by month 1 and remained significantly lower than placebo through month 6. The mean reduction in SOL was approximately 14 minutes greater with eszopiclone than with placebo at endpoint.
• Wake-after-sleep-onset (WASO): Eszopiclone produced statistically significant reductions in WASO versus placebo across the full study duration.
• Total sleep time (TST): Patients on eszopiclone reported about 45 minutes more sleep per night than placebo by month 6.
• No evidence of tolerance: Response did not diminish over the six-month treatment period, which was notable at a time when most hypnotic trials lasted only two to four weeks 1.

A subsequent analysis by Roth et al. (2005) confirmed that next-day functioning, measured by daytime alertness and ability to function scales, also improved with eszopiclone compared to placebo 5.

The FDA later approved eszopiclone at 1 mg, 2 mg, and 3 mg. In 2014, the agency recommended that the starting dose be lowered to 1 mg because pharmacokinetic data showed next-morning impairment at higher doses, particularly in older adults 6.

Trazodone Efficacy Data

Trazodone's insomnia evidence is smaller and shorter. The most-cited trial is a two-week study by Walsh et al. (1998) enrolling 306 patients with primary insomnia. Trazodone 50 mg reduced subjective SOL in week 1 compared to placebo, but this benefit was no longer statistically significant by week 2 7.

Mendelson (2005), writing in the Journal of Clinical Psychiatry, reviewed the off-label sleep literature for trazodone and concluded that the drug was "widely prescribed despite limited RCT support." He noted that most positive signals came from studies in depressed patients with comorbid insomnia, where separating the antidepressant benefit from the hypnotic benefit is difficult 2a.

A polysomnography study by Roth et al. (2011) measured objective sleep architecture changes with trazodone 50 mg in 20 subjects with primary insomnia. Trazodone increased total sleep time by approximately 35 minutes and improved sleep efficiency, but the sample was too small to draw firm efficacy conclusions, and the treatment period lasted only one week 8.

Dr. Andrew Krystal, then at Duke University Medical Center, summarized the situation in a 2009 review: "Trazodone is probably the most commonly used agent for insomnia in the United States, yet there are remarkably few controlled data to support its use for this indication" 9.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline gave trazodone a "WEAK AGAINST" recommendation for sleep-onset insomnia and sleep-maintenance insomnia, noting that the quality of evidence was very low 10.

Indirect Efficacy Comparison

Because no randomized trial has compared eszopiclone to trazodone directly, the comparison below is assembled from the studies described above. Different patient populations, endpoints, and trial durations limit the precision of these cross-trial inferences.

Sleep-onset latency: Eszopiclone demonstrated consistent, sustained SOL reductions across six months (Krystal 2003). Trazodone showed a SOL benefit in week 1 that faded by week 2 (Walsh 1998). The eszopiclone data are more durable by a wide margin.

Sleep maintenance (WASO): Eszopiclone significantly reduced WASO over 6 months 1. Trazodone's effect on WASO has not been convincingly demonstrated in adequately powered trials.

Total sleep time: Both drugs increase self-reported total sleep time. Eszopiclone added roughly 45 minutes over placebo at month 6. Trazodone added approximately 35 minutes in a one-week PSG study of 20 patients 8. These numbers come from very different designs and cannot be compared numerically with confidence.

Duration of evidence: This is the sharpest difference. Eszopiclone has six-month controlled data showing no tolerance development. The longest controlled trazodone insomnia trial lasted two weeks, and efficacy appeared to wane during that period 7.

Guideline positioning: The AASM 2017 guideline recommended eszopiclone for both sleep-onset and sleep-maintenance insomnia (WEAK FOR). Trazodone received a WEAK AGAINST recommendation for both insomnia subtypes 10.

Side-Effect Profiles

Eszopiclone's most distinctive adverse effect is dysgeusia, an unpleasant metallic or bitter taste reported by up to 34% of patients in the 3 mg group during the Krystal 2003 trial 1. Other common effects include dizziness, dry mouth, and headache. The FDA has flagged rare complex sleep behaviors (sleep-driving, sleep-walking) as class warnings for all sedative-hypnotics, including eszopiclone 6.

Trazodone's side-effect profile at sleep doses typically includes morning grogginess, orthostatic hypotension, and dry mouth. Priapism occurs rarely (estimated 1 in 6,000 to 1 in 8,000 male patients) but is a medical emergency that requires patient counseling 4. Cardiac QT prolongation has been reported at higher doses, so an ECG before prescribing may be reasonable for patients with cardiac risk factors 11.

The tolerability trade-off often shapes prescribing. Clinicians who want to avoid Schedule IV prescriptions or who treat patients with substance-use histories may lean toward trazodone. Clinicians prioritizing data-backed efficacy and sustained response may prefer eszopiclone.

Dependence, Withdrawal, and Scheduling

Eszopiclone is a DEA Schedule IV controlled substance. Physical dependence can develop, and abrupt discontinuation after prolonged use may cause rebound insomnia lasting one to two nights. In the Krystal 2003 study, rebound insomnia during the two-week placebo run-out was mild and brief 1.

Trazodone is not a controlled substance. It does not produce the GABAergic withdrawal pattern seen with benzodiazepine-receptor agonists. It can, however, cause a serotonin-discontinuation syndrome if stopped abruptly after extended use at antidepressant doses. At sleep doses of 25 to 100 mg, this risk appears minimal based on available case-report data 4.

For patients with a history of sedative-hypnotic misuse, trazodone's unscheduled status is a practical advantage. The AASM guideline still recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment for chronic insomnia regardless of the pharmacologic agent chosen 10.

Special Populations

Older adults: The American Geriatrics Society Beers Criteria list both non-benzodiazepine hypnotics (including eszopiclone) and trazodone as potentially inappropriate medications for adults 65 and older due to fall risk and excessive sedation 12. If eszopiclone is used, the recommended starting dose in this group is 1 mg. Trazodone doses above 50 mg for sleep carry increasing anticholinergic burden and hypotension risk in geriatric patients.

Comorbid depression: Trazodone has an indication for major depressive disorder at doses of 150 to 400 mg. For patients with comorbid depression and insomnia, trazodone at antidepressant doses may address both conditions simultaneously, though monotherapy remission rates with trazodone for depression are modest compared with modern SSRIs 4.

Comorbid anxiety: Eszopiclone 3 mg demonstrated anxiolytic effects in a study of patients with primary insomnia and co-occurring generalized anxiety disorder (Pollack et al., 2008). The Hamilton Anxiety Rating Scale score improved significantly versus placebo 13.

Cost and Access

Generic eszopiclone became available in the United States in 2014. A 30-day supply of generic eszopiclone 1 mg to 3 mg typically costs $10 to $40 at retail pharmacies with a discount coupon.

Generic trazodone has been available for decades. A 30-day supply of 50 mg tablets typically costs $4 to $15. The low cost is one reason trazodone dominates prescribing volume for insomnia.

Both drugs are covered by most commercial formularies and by Medicare Part D. Prior authorization is uncommon for either agent in generic form.

Choosing Between Them: Clinical Decision Points

The decision rests on a few concrete factors:

1. Strength of evidence: Eszopiclone wins. Six months of controlled data versus two weeks.
2. Scheduling concerns: Trazodone wins. No controlled-substance classification.
3. Comorbid depression: Trazodone may serve double duty at higher doses.
4. Taste sensitivity: Patients who cannot tolerate the metallic taste (34% in the 3 mg group) will not stay on eszopiclone.
5. Substance-use history: Trazodone is preferred in patients with prior sedative-hypnotic misuse.
6. Sleep architecture: Trazodone may increase slow-wave sleep in some patients, while eszopiclone primarily reduces light-sleep fragmentation 8.

Neither drug replaces CBT-I, which the AASM recommends as the first intervention for chronic insomnia in adults 10. Pharmacotherapy is most appropriate when CBT-I is unavailable, has been tried and failed, or when short-term relief is needed while behavioral treatment takes effect.

What the Prescribing Data Show

Despite weaker trial data, trazodone continues to dominate U.S. insomnia prescribing. A study using National Ambulatory Medical Care Survey (NAMCS) data found that trazodone accounted for more insomnia visits than any single FDA-approved hypnotic between 2002 and 2012 2. The preference likely reflects three factors: no DEA scheduling, lower cost, and physician familiarity from its decades-long availability as a generic antidepressant.

Eszopiclone prescriptions declined after generic availability paradoxically reduced marketing spend and after the FDA's 2014 dose-reduction recommendation raised next-day impairment concerns 6. The trend illustrates a broader pattern in insomnia treatment: clinical evidence and prescribing volume do not always move in the same direction.

Starting dose for eszopiclone in adults is 1 mg at bedtime, titrated to 2 or 3 mg if needed; for trazodone, 25 to 50 mg at bedtime, titrated in 25 mg increments to a maximum of 100 mg for sleep, with re-evaluation at 7 to 14 days 10.